Cargando…

Modelling the cost-effectiveness of catch-up ‘MenB’ (Bexsero) vaccination in England

We assessed the cost-effectiveness of offering catch-up vaccination with Bexsero against meningococcal disease to children too old to receive the vaccine under the recently introduced infant programme. Offering catch-up vaccination to increasingly older children is less economically attractive becau...

Descripción completa

Detalles Bibliográficos
Autores principales:	Christensen, Hannah, Trotter, Caroline L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science 2017
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418563/ https://www.ncbi.nlm.nih.gov/pubmed/27923519 http://dx.doi.org/10.1016/j.vaccine.2016.11.076

Ejemplares similares

Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study
por: Christensen, Hannah, et al.
Publicado: (2014)

Health and Economic Outcomes of Introducing the New MenB Vaccine (Bexsero) into the Italian Routine Infant Immunisation Programme
por: Tirani, Marcello, et al.
Publicado: (2015)

Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine
por: Hong, Eva, et al.
Publicado: (2016)

Routine vaccination against MenB: Considerations for implementation
por: Kaaijk, Patricia, et al.
Publicado: (2014)

Phase Variation of NadA in Invasive Neisseria meningitidis Isolates Impacts on Coverage Estimates for 4C-MenB, a MenB Vaccine
por: Green, Luke R., et al.
Publicado: (2018)

The Long Road to an Effective Vaccine for Meningococcus Group B (MenB)
por: Shea, Michael W.
Publicado: (2013)

Cost-effectiveness of a male catch-up human papillomavirus vaccination program in the Netherlands
por: Simons, Joost J.M., et al.
Publicado: (2022)

Cost-effectiveness of alternative strategies for vaccination of adolescents against serogroup B IMD with the MenB-FHbp vaccine in Canada
por: Breton, Marie-Claude, et al.
Publicado: (2020)

Product review on the IMD serogroup B vaccine Bexsero®
por: Deghmane, Ala-Eddine, et al.
Publicado: (2022)

A physician’s guide to the 2-dose schedule of MenB-FHbp vaccine
por: McDaniel, Angee, et al.
Publicado: (2019)

Crystal structures of human Fabs targeting the Bexsero meningococcal vaccine antigen NHBA
por: Maritan, Martina, et al.
Publicado: (2017)

Perceptions and Knowledge About the MenB Vaccine Among Parents of High School Students
por: Richardson, Eric, et al.
Publicado: (2021)

Exploring the population-level impact of MenB vaccination via modeling: Potential for serogroup replacement
por: Hogea, Cosmina, et al.
Publicado: (2015)

‘Be on the TEAM’ Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents
por: Carr, Jeremy, et al.
Publicado: (2020)

The Serogroup B Meningococcal Vaccine Bexsero Elicits Antibodies to Neisseria gonorrhoeae
por: Semchenko, Evgeny A, et al.
Publicado: (2019)

UK parents’ attitudes towards meningococcal group B (MenB) vaccination: a qualitative analysis
por: Jackson, Cath, et al.
Publicado: (2017)

Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis
por: Gasparini, Roberto, et al.
Publicado: (2016)

Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine — Advisory Committee on Immunization Practices, 2016
por: Patton, Monica E., et al.
Publicado: (2017)

Meningococcal Carriage in Military Recruits and University Students during the Pre MenB Vaccination Era in Greece (2014-2015)
por: Tryfinopoulou, Kyriaki, et al.
Publicado: (2016)

Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data
por: Beeslaar, Johannes, et al.
Publicado: (2020)

Multi‐component meningococcal serogroup B (MenB)‐4C vaccine induces effective opsonophagocytic killing in children with a complement deficiency
por: van den Broek, B., et al.
Publicado: (2019)

Progressive Decrease in the Potential Usefulness of Meningococcal Serogroup B Vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northern Spain
por: Pérez-Trallero, Emilio, et al.
Publicado: (2014)

Mouse Model of Small for Gestational Age Offspring with Catch-up Growth Failure and Dysregulated Glucose Metabolism in Adulthood
por: Moon, Hyeon Seok, et al.
Publicado: (2022)

Meningococcal Antigen Typing System (MATS)-Based Neisseria meningitidis Serogroup B Coverage Prediction for the MenB-4C Vaccine in the United States
por: Rajam, Gowrisankar, et al.
Publicado: (2017)

The Bexsero Neisseria meningitidis serogroup B vaccine antigen NHBA is a high-affinity chondroitin sulfate binding protein
por: Mubaiwa, Tsitsi D., et al.
Publicado: (2018)

2722. Effects of Sex, Age, and Race on Immunogenicity of MenB-FHbp, a Bivalent Meningococcal B Vaccine: A Pooled Evaluation of Clinical Trial Data
por: Beeslaar, Johannes, et al.
Publicado: (2019)

MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies
por: Beeslaar, Johannes, et al.
Publicado: (2020)

Safety profile of MenB-FHBp vaccine among adolescents: data from surveillance of Adverse Events Following Immunization in Puglia (Italy), 2018–2020
por: Stefanizzi, Pasquale, et al.
Publicado: (2022)

Molecular characterization of invasive Neisseria meningitidis isolates collected in Lithuania (2009-2019) and estimation of serogroup B meningococcal vaccine 4CMenB and MenB-Fhbp coverage
por: Sereikaitė, Emilija, et al.
Publicado: (2023)

Surging trends in prescriptions and costs of antidepressants in England amid COVID-19
por: Rabeea, Shahad A., et al.
Publicado: (2021)

6. Pentavalent Meningococcal (MenABCWY) Vaccine is Safe and Well Tolerated With Immunogenicity Noninferior to Coadministered MenB-FHbp and MenACWY-CRM in a Phase 2 Study of Healthy Adolescents and Young Adults
por: Peterson, James, et al.
Publicado: (2020)

Modelling the impact of COVID-19 and routine MenACWY vaccination on meningococcal carriage and disease in the UK
por: Hadley, Liza, et al.
Publicado: (2023)

01. Serum Bactericidal Activity Against Circulating and Reference Strains of Meningococcal Serogroup B in the United States: A Review of Meningococcal Serogroup B (MenB) Vaccines in Adolescents and Young Adults
por: Coyne-Beasley, Tamera, et al.
Publicado: (2021)

Erratum for Rajam et al., “Meningococcal Antigen Typing System (MATS)-Based Neisseria meningitidis Serogroup B Coverage Prediction for the MenB-4C Vaccine in the United States”
por: Rajam, Gowrisankar, et al.
Publicado: (2019)

Modelling the impact of COVID-19 and routine MenACWY vaccination on meningococcal carriage and disease in the UK – ERRATUM
por: Hadley, Liza, et al.
Publicado: (2023)

Childhood vaccinations: playing catch-up
por: The Lancet Child & Adolescent Health
Publicado: (2021)

1737. Cost-Effectiveness Analysis of Catch-Up Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine
por: Rozenbaum, Mark, et al.
Publicado: (2023)

Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults
por: Presa, Jessica, et al.
Publicado: (2023)

Fatalities associated with gabapentinoids in England (2004–2020)
por: Kalk, Nicola J., et al.
Publicado: (2022)

Distribution of Bexsero® Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: Implications for immunisation
por: Brehony, Carina, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qaic6vlk109uuc8jftl07a2jg5